Clinical trial
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial…
NCT00334893 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00334893 |
|---|---|
| Title | Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer |
| Official title | A Multi-Center Phase II Study of the Halichondrin B Analog E7389 in Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer |
| Intervention type | Drug |
| Interventions | eribulin mesylate |
| Enrollment | 74 |
| Start date | Apr 1, 2006 |
| Primary completion | Mar 1, 2012 |
| Completion | Mar 1, 2012 |
| First posted | Jun 8, 2006 |
| Last update posted | Nov 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: